{"schema_version":"secwatch.filing_event.v1","accession":"0001785530-23-000027","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.235122+00:00","generated_at":"2026-06-11T18:39:26.866568+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Werewolf Therapeutics Q2 net loss narrows to $5.1M; cash runway through Q4 2024; WTX-124 data expected 4Q23","bullets":["Net loss $5.1M ($0.16/diluted share) vs $14.6M ($0.83) in Q2 2022; collaboration revenue $8.1M (up from $4.1M).","Cash and equivalents $137.5M at June 30, 2023; restricted cash $21.2M; runway through at least Q4 2024.","R&D expenses fell to $9.6M from $13.9M YoY on lower manufacturing costs and purchase-order closeouts.","WTX-124 Phase 1/1b enrollment ongoing; initial monotherapy safety, PK, and biomarker data anticipated in 4Q 2023.","Jazz Pharmaceuticals' JZP898 (formerly WTX-613) IND cleared July 2023 under the Werewolf collaboration."],"urls":{"canonical":"https://secwatch.observer/filing/0001785530-23-000027","json":"https://secwatch.observer/filing/0001785530-23-000027.json","markdown":"https://secwatch.observer/filing/0001785530-23-000027.md","text":"https://secwatch.observer/filing/0001785530-23-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000178553023000027/0001785530-23-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000178553023000027/howl-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:39:26.866568+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d87cee55f45aaed529803cb4d8d35fa90f8140af","claim":"Werewolf Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $8.1 million, net income $5.1 million.","evidence_excerpt":"Collaboration revenue was $8.1 million for the second quarter of 2023, compared to $4.1 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785530/000178553023000027/0001785530-23-000027-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$8.1 million"},{"label":"Net income","value":"$5.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}